26 May 2025 in Journal of Nanobiotechnology
Immune checkpoint blockade therapy (iCBT) has revolutionized cancer treatment, however, there is a low response rate, especially in treating postsurgical reoccurring tumors. Vaccine based immunotherapy can sensitize iCBT, but its development was largely hindered by inefficient delivery and high requirements of storage. In this study, the vaccine loaded with immunostimulant was employed to improve iCBT-based adjuvant postsurgical therapy. A lyophilized, antigen E7 peptide and manganese ion (Mn2+) co-delivered tumor vaccine was developed based on lipid nanoparticles (EM@LNP). The vaccination efficacy was examined in both prophylactic and therapeutic schemes in murine subcutaneous models, the synergetic effect of vaccination combined with anti-PD-1 therapy was further investigated in post-operative tumor model. EM@LNP vaccination elicited effective CD8+T cell response through modulating tumor immunosuppressive microenvironment and conferring immune memory, demonstrating potent immunization in both preventive and therapeutic schemes. What’s more, EM@LNP vaccination orchestrated with iCBT, efficiently repressing tumor recurrence. Further mechanism studies using inhibitor for cells invitro and the investigation using STING−/− mice confirmed that the cGAS-STING signaling pathway activated by Mn2+ is indispensable for LNP vaccination and the coordination with iCBT-based adjuvant immunotherapy. In summary, this study shows a lyophilized LNP vaccine could significantly amplify iCBT efficiency, providing a translational strategy of adjuvant immunotherapy for treating postsurgical tumor recurrence.
20 November 2026 in Science Advances
Bioorthogonal prodrug activation offers a promising approach for site-specific drug release, significantly reducing the systemic toxicity associated with conventional chemotherapy. However, challenges remain in precisely controlling prodrug activation at the target site while maintaining optimal selectivity, reactivity, and potency. Here, we report a dual-targeting peptide, TzFFY p HH, that integrates on-membrane enzyme-instructed self-assembly (EISA) with bioorthogonal chemistry to enable selective chemotherapy. Exploiting the overexpression of alkaline phosphatase (ALP) and programmed death-ligand 1 (PD-L1) on cancer cells, TzFFY p HH selectively anchors and self-assembles on the cancer cell membrane, enriching tetrazine (Tz) handles that act as bioorthogonal reactors to activate a trans -cyclooctene (TCO)-caged prodrug (TCO-Dox) for precise drug release. Upon topical administration, TzFFY p HH forms a hydrogel at subcutaneous tumor sites, enabling in situ prodrug activation for effective tumor inhibition. Notably, this localized chemotherapy elicits a potent antitumor immune response, which, when combined with anti-programmed death-1 antibody (αPD-1), synergistically potentiates therapeutic outcomes. By coupling supramolecular self-assembly with bioorthogonal reactivity on the cell membrane, this work establishes a chemically programmable platform for spatiotemporally controlled prodrug activation and provides a general strategy for integrating localized chemotherapy with immunotherapy.